Stockscreener 앱 받기
917.50
0.06%
-0.55
시간 외 거래:
917.47
-0.03
-0.00%
Lilly Eli Co 주식(LLY)의 최신 뉴스
England to Review Rejection of Eli Lilly Alzheimer’s Drug for NHS - Bloomberg.com
Lilly’s experimental diabetes shot yields record weight loss in study - UnionLeader.com
Triple crown: T2D purse for Lilly’s phase III retatrutide? - BioWorld MedTech
Leerink reiterates Eli Lilly stock rating on diabetes drug data - Investing.com
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals - The Motley Fool
Lilly’s Retatrutide Shows Significant Improvement In Weight Loss and Blood Sugar - WSJ
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals - The Motley Fool
Eli Lilly's GLP-1 Revenue Lead in 2025: Competition & Valuation AnalysisNews and Statistics - IndexBox
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial - drugdiscoverytrends.com
Eli Lilly Targets Crohn’s Disease With New Combo Trial That Could Extend Its IBD Franchise - TipRanks
Eli Lilly's (LLY) Retatrutide Shows Promise in Diabetes Market - GuruFocus
LLY Shares Boosted by Positive Phase III Diabetes Trial Results - GuruFocus
Eli Lilly Advances EMERALD-3: A New Oral Bet in Ulcerative Colitis - TipRanks
Morgan Stanley reiterates Overweight on Eli Lilly stock after trial data - Investing.com
Eli Lilly Says Experimental Diabetes Drug Shows Weight Loss Of 17% - Benzinga
Eli Lilly Stock (LLY) Rises. The Pharma Giant Has Reported Some Very Good News - TipRanks
First look at Eli Lilly’s planned $3.5 billion Lehigh Valley plant: When will construction start, how much traffic will it cause? - The Morning Call
Eli Lilly’s ‘triple-G’ shows potency, raises concerns - statnews.com
Wolfe Research reiterates Eli Lilly stock rating on diabetes trial - Investing.com
Truist reiterates Eli Lilly stock Buy rating on retatrutide data - Investing.com
Eli Lilly (LLY) Stock: Retatrutide Cuts Blood Sugar and Drives 17% Weight Loss in Trial - CoinCentral
Lilly’s Experimental Diabetes Shot Yields Record Weight Loss in Study - Bloomberg.com
Eli Lilly’s Triple-Action Drug Retatrutide Shatters Diabetes Treatment Benchmarks - streamlinefeed.co.ke
Eli Lilly (LLY) Achieves Key Results in Weight Loss Therapy Tria - GuruFocus
Eli Lilly’s next-generation obesity drug delivers strong results in late-stage trial - Proactive financial news
Lilly's next-gen drug shows significant blood sugar, weight reduction in diabetes trial - Reuters
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes - Eli Lilly
Eli Lilly’s ‘triple-G’ drug leads to significant blood sugar, weight reductions in diabetes trial - statnews.com
Lilly's Phase 3 diabetes drug helped patients lose 36.6 pounds - Stock Titan
Eli Lilly and Company $LLY Shares Sold by Groupama Asset Managment - MarketBeat
Investment Research Partners LLC Invests $1.32 Million in Eli Lilly and Company $LLY - MarketBeat
Opes Wealth Management LLC Cuts Stake in Eli Lilly and Company $LLY - MarketBeat
Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect - Eli Lilly
Eli Lilly (LLY) Reports Positive Phase 3 Pediatric Data for EBGLYSS - Insider Monkey
Eli Lilly (NYSE:LLY) Advances Pediatric Dermatology Growth With Strong S&P 500 - Kalkine Media
Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.4% Following Analyst Downgrade - MarketBeat
Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (I'd Buy Both) (RHHBY) - Seeking Alpha
Eli Lilly Technical Analysis: Is The Selloff Over?Eli Lilly (NYSE:LLY) - Benzinga
High-tech workers, manufacturing legacy helped Lehigh Valley win ‘gauntlet’ for $3.5B Lilly plant - LehighValleyNews.com
Parkland School Board members skeptical of tax break for Eli Lilly - The Morning Call
Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum? - Yahoo Finance Singapore
Eli Lilly and Company (LLY) Gets Downgraded to Reduce From Hold by HSBC – Here’s Why - Insider Monkey
Wilmington Savings Fund Society FSB Lowers Stake in Eli Lilly and Company $LLY - MarketBeat
Lilly spending $1.8B to update Indianapolis manufacturing operations - Indianapolis Business Journal
Portus Wealth Advisors LLC Acquires Shares of 1,675 Eli Lilly and Company $LLY - MarketBeat
Danske Bank A S Buys Shares of 671,064 Eli Lilly and Company $LLY - MarketBeat
Mizuho Markets Cayman LP Acquires 84,404 Shares of Eli Lilly and Company $LLY - MarketBeat
Silvant Capital Management LLC Raises Holdings in Eli Lilly and Company $LLY - MarketBeat
Livforsakringsbolaget Skandia Omsesidigt Trims Position in Eli Lilly and Company $LLY - MarketBeat
Caitong International Asset Management Buys Eli Lilly Shares - National Today
Pre-market Movement in the U.S. Stock Market: Novo-Nordisk A/S shares fell more than 2% as research results for structure-based obesity drugs approach those of Novo-Nordisk A/S and Eli Lilly and Co. - 富途牛牛
Coldstream Capital Management Inc. Increases Stake in Eli Lilly and Company $LLY - MarketBeat
Cim Investment Management Inc. Cuts Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Holdings Lifted by Advisory Services Network LLC - MarketBeat
J&J Reigns as Top Pharma by Revenue While Lilly Leapfrogs on Strong Obesity Sales - BioSpace
Parkland School District considers tax breaks for Eli Lilly’s proposed manufacturing campus - WFMZ.com
How did the Lehigh Valley land the Eli Lilly deal? Company executive offers insight - MSN
'Pennsylvania is winning again': Eli Lilly success story lauded at LVEDC meeting - WFMZ.com
Weight Loss Drug Market Analysis 2026: Leaders, Oral Drugs & Competitive LandscapeNews and Statistics - IndexBox
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - AOL.com
Gov. Josh Shapiro touts Lilly deal as Lehigh Valley celebrates $3.5B investment: "We're competing again" - Lehigh Daily
Eli Lilly’s road to Pennsylvania, details of new $3.5B plant, celebrated in the Lehigh Valley - lehighvalleylive
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Eli Lilly and Company (NYSE:LLY) Trading Down 5.9% Following Analyst Downgrade - MarketBeat
Lilly Gets Lone Sell From HSBC Ahead of Deeper Weight Loss Drug Price Cuts - Bloomberg.com
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Lilly Gets Rare Downgrade as Analysts Question Hype Over GLP-1 Pills and Zepbound's Cash Sales - 富途牛牛
Eli Lilly, Micron among market cap stock movers on Tuesday - Investing.com
0.13%
1.01%
자본화:
|
볼륨(24시간):